BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (Nasdaq:CELG) today announced physicians from leading cancer research centers presented data at the American Society of Clinical Oncology from several clinical studies of REVLIMID (lenalidomide) in multiple myeloma. Among these were updated results from two large cooperative group trials of REVLIMID in combination with dexamethasone in newly diagnosed patients. Both studies reported a survival advantage and improved complete response rates for REVLIMID when combined with dexamethasone.
